{"title":"Antitumor Necrosis Factor-Refractory Esophageal Lesions in Crohn's Disease Successfully Treated With Upadacitinib.","authors":"Naohiro Nakamura, Yusuke Honzawa, Yuka Ito, Yasuki Sano, Naoto Yagi, Eiko Saito, Norimasa Fukata, Makoto Naganuma","doi":"10.14309/crj.0000000000001713","DOIUrl":null,"url":null,"abstract":"<p><p>A 39-year-old man with a 5-year history of ileocolonic Crohn's disease received treatment with 6-mercaptopurine and adalimumab. A computed tomography scan was performed due to a persistent cough, revealing esophageal wall thickening. Esophagogastroduodenoscopy identified multiple longitudinal ulcers throughout the esophagus. Despite infliximab treatment, the esophageal lesions deteriorated, leading to the initiation of upadacitinib for antitumor necrosis factor-refractory esophageal lesions. Consequently, all esophageal lesions were healed, and serum biomarkers returned negative results. Although upadacitinib is effective for patients with ileocolonic Crohn's disease, this is the first case demonstrating its efficacy for refractory esophageal lesions.</p>","PeriodicalId":7394,"journal":{"name":"ACG Case Reports Journal","volume":"12 5","pages":"e01713"},"PeriodicalIF":0.6000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084109/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACG Case Reports Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14309/crj.0000000000001713","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
A 39-year-old man with a 5-year history of ileocolonic Crohn's disease received treatment with 6-mercaptopurine and adalimumab. A computed tomography scan was performed due to a persistent cough, revealing esophageal wall thickening. Esophagogastroduodenoscopy identified multiple longitudinal ulcers throughout the esophagus. Despite infliximab treatment, the esophageal lesions deteriorated, leading to the initiation of upadacitinib for antitumor necrosis factor-refractory esophageal lesions. Consequently, all esophageal lesions were healed, and serum biomarkers returned negative results. Although upadacitinib is effective for patients with ileocolonic Crohn's disease, this is the first case demonstrating its efficacy for refractory esophageal lesions.
期刊介绍：
ACG Case Reports Journal is a peer-reviewed, open-access publication that provides GI and hepatology fellows, private practice clinicians, and other healthcare providers an opportunity to share interesting case reports with their peers and with leaders in the field. ACG Case Reports Journal publishes case reports, images, videos and letters to the editor in all topics of gastroenterology and hepatology, including: Biliary Colon Endoscopy Esophagus Functional Bowel Disorders Inflammatory Bowel Disease Liver Nutrition and Obesity Pancreas Pathology Pediatric Small Bowel Stomach.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
